TC
AUTL

Truvestments Capital’s Autolus Therapeutics AUTL Stock Holding History

Truvestments Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$1.18K – 1042
2024
Q4 		$1.18K Buy
+500
New +$1.69K ﹤0.01% 909

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Truvestments Capital's AUTL Position: Q1 2025 in Review

Truvestments Capital sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 500 shares — an estimated $1.18K sold.

Truvestments Capital first reported a position in AUTL in Q4 2024 and held it in 1 quarter. The position peaked at $1.18K in Q4 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Truvestments Capital reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Truvestments Capital sold 500 Autolus Therapeutics shares in Q1 2025, an estimated $1.18K.
  • Truvestments Capital first reported a position in Autolus Therapeutics in Q4 2024 and held it in 1 quarter.
  • Truvestments Capital's Autolus Therapeutics position peaked at $1.18K in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Truvestments Capital's 13F filing for Q1 2025, filed 14 May 2025.